Drug Profile

SL 325

Alternative Names: SL-325

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shattuck Labs
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Tumour necrosis factor member 25 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Inflammatory bowel diseases

Most Recent Events

14 Aug 2025 Shattuck Labs expects IND approval for Inflammatory bowel disease from the US FDA in the third quarter of 2025
14 Aug 2025 Shattuck plans a phase I trial for in Inflammatory bowel disease (In volunteers) in third quarter of 2025
05 Aug 2025 Shattuck plans a phase II clinical trials for in Inflammatory bowel disease and autoimmune disorders in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com